Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by willibrichon Sep 02, 2010 1:54pm
756 Views
Post# 17408971

share price riddle ?

share price riddle ?Yes it is somewhat puzzling that QEI's share price has not really changed much since the big announcement on August 9.  Especially in light of the increased  trading volumes.
 And I say BIG announcement.......................... because as Sprott indicated, QEI will soon be going from an exploration company in Columbia to a production company. How much production , we do not know.
However , if you read the M & A  released on August 30................you will see   ''  It is anticipated that the perforating and testing of the well will commence in the latter part of the third quarter , 2010 and  last approximately 30 to 45 days ''
Now this tells me 2 things.  1)  Flow testing of 100 feet of pay over 4 different formations only takes 30 to 45 days if there are significant pressures and production  anticipated,  which need to be confirmed in order to arrange for commercial production infrastructure. And confirmation of  commercial flow rates is achieved by monitoring formation pressues during flow testing. If pressures do not drop much over a period of some days of production, then it indicates that the pool of oil being flow tested is large. This all takes time.
                                                    2) Perforations are used to increase flow rates from a formation. Again , there seems to be some significant commercial flows anticipated.

It seems to me that the market is taking an '' I'm from MIssouri '' posture here. But one item of note is that with the endorsement of Sprott , we small fish retail investors have  been given a rare opportunity. An opportunity to invest in a company which Sprott has identified, as having good management and good prospects going forward. So many times I have seen these Sprott picks go up 20 % , 30 %  etc. within days of being mentioned. Sprott's involvement gives me a great deal of comfort. 

Hey it is still a speculative stock. But now there is alot more hope for us QEI shareholders

  
Bullboard Posts